Metabolic syndrome and outcomes following early-stage breast cancer

Breast Cancer Research and Treatment

Volumn 148, Issue 2, 2014, Pages 363-377

  Calip, Gregory S ^a,b,c   Malone, Kathleen E ^b,c   Gralow, Julie R ^d   Stergachis, Andy ^b   Hubbard, Rebecca A ^b,e   Boudreau, Denise M ^b,e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c USA   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

^e GROUP HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Breast cancer; Metabolic syndrome; Mortality; Recurrence; Second primary breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROGESTERONE RECEPTOR; TRIACYLGLYCEROL; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST DISEASE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY CANCER; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENTAL FINDING; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASMS SUBDIVIDED BY ANATOMICAL SITE; OUTCOME ASSESSMENT; POPULATION RESEARCH; RETROSPECTIVE STUDY; SECOND BREAST CANCER EVENT; SECOND CANCER; TUMOR VOLUME; VERY ELDERLY; WEIGHT GAIN; YOUNG ADULT; ADOLESCENT; BODY MASS; BREAST TUMOR; COMPLICATION; ENZYME IMMUNOASSAY; METABOLISM; MORTALITY; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BODY MASS INDEX; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84911968225     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3157-6     Document Type: Article

References (65)

1. American Cancer Society (2013) Breast cancer facts & figures 2013–2014. American Cancer Society Inc., Atlanta
2. American Cancer Society (2012) Cancer treatment and survivorship facts & figures 2012–2013. American Cancer Society Inc., Atlanta
3. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE, American Society of Clinical O (2013) Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(7):961–965. doi:10.1200/JCO.2012.45.9859
4. Ritchie CS, Kvale E, Fisch MJ (2011) Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract 7(6):371–374. doi:10.1200/JOP.2011.000460
5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart A, National Heart L, Blood I (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17):2735–2752. doi:10.1161/CIRCULATIONAHA.105.169404
6. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ (2010) The metabolic syndrome. Lancet 375(9710):181–183. doi:10.1016/S0140-6736(09)61794-3
7. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578. doi:10.1016/S0140-6736(08)60269-X
8. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20(1):42–51
9. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Rafaniello C, Giugliano D (2013) Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause 20(12):1301–1309. doi:10.1097/GME.0b013e31828ce95d
10. Healy LA, Ryan AM, Carroll P, Ennis D, Crowley V, Boyle T, Kennedy MJ, Connolly E, Reynolds JV (2010) Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin oncol 22(4):281–288. doi:10.1016/j.clon.2010.02.001
11. Tian YF, Chu CH, Wu MH, Chang CL, Yang T, Chou YC, Hsu GC, Yu CP, Yu JC, Sun CA (2007) Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer 14(3):669–677. doi:10.1677/ERC-06-0089
12. Baglietto L, Severi G, English DR, Krishnan K, Hopper JL, McLean C, Morris HA, Tilley WD, Giles GG (2010) Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiol Biomark Prev 19(2):492–502. doi:10.1158/1055-9965.EPI-09-0532
13. Kaaks R (2001) Plasma insulin, IGF-I and breast cancer. Gynecol Obstet fertil 29(3):185–191
14. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393–1396. doi:10.1016/S0140-6736(97)10384-1
15. Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, Brancati FL, Wolff AC (2011) Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 29(1):40–46. doi:10.1200/JCO.2009.27.3011
16. Ewertz M, Jensen MB, Gunnarsdottir KA, Hojris I, Jakobsen EH, Nielsen D, Stenbygaard LE, Tange UB, Cold S (2011) Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 29(1):25–31. doi:10.1200/JCO.2010.29.7614
17. Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 86(3):823–835
18. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300(23):2754–2764. doi:10.1001/jama.2008.824
19. Dignam JJ, Mamounas EP (2004) Obesity and breast cancer prognosis: an expanding body of evidence. Ann Oncol 15(6):850–851
20. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Erien D, Collins J, Snyder R, Thurlimann B, Fey MF, Mendiola C, Werner ID, Simoncini E, Crivellari D, Gelber RD, Goldhirsch A, International Breast Cancer Study G (2004) Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 15(6):875–884
21. Chen X, Lu W, Zheng W, Gu K, Chen Z, Zheng Y, Shu XO (2010) Obesity and weight change in relation to breast cancer survival. Breast Cancer Res Treat 122(3):823–833. doi:10.1007/s10549-009-0708-3
22. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B (2008) Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 111(2):329–342. doi:10.1007/s10549-007-9785-3
23. de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjold B, Gutierez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Di Leo A, Piccart-Gebhart M (2010) The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat 119(1):145–153. doi:10.1007/s10549-009-0512-0
24. Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95(19):1467–1476
25. Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH (2013) Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol 24(10):2506–2514. doi:10.1093/annonc/mdt224
26. Cancer Surveillance System http://www.fhcrc.org/en/labs/phs/projects/cancer-surveillance-system.html
27. Surveillance Epidemiology and End Results (SEER) Program Overview of the SEER Program http://seer.cancer.gov/about/overview.html
28. Boudreau DM, Yu O, Chubak J, Wirtz HS, Bowles EJ, Fujii M, Buist DS (2014) Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat 144(2):405–416. doi:10.1007/s10549-014-2870-5
29. Wirtz HS, Buist DS, Gralow JR, Barlow WE, Gray S, Chubak J, Yu O, Bowles EJ, Fujii M, Boudreau DM (2013) Frequent antibiotic use and second breast cancer events. Cancer Epidemiol Biomark Prev 22(9):1588–1599. doi:10.1158/1055-9965.EPI-13-0454
30. Buist DS, Abraham LA, Barlow WE, Krishnaraj A, Holdridge RC, Sickles EA, Carney PA, Kerlikowske K, Geller BM, Breast Cancer Surveillance C (2010) Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer. Breast Cancer Res Treat 124(3):863–873. doi:10.1007/s10549-010-1106-6
31. Group Health Breast Cancer Surveillance Registry http://www.grouphealthresearch.org/surveillanceproject Accessed 15 June 2011
32. Saunders KW, Davis RL, Stergachis A (2005) Group health cooperative. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. J. Wiley, Chichester, Hoboken, pp 223–239
33. Boudreau DM, Doescher MP, Jackson JE, Fishman PA, Saver BG (2004) Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications. Ann Pharmacother 38(7–8):1317–1318. doi:10.1345/aph.1D569
34. Buist DS, LaCroix AZ, Brenneman SK, Abbott T 3rd (2004) A population-based osteoporosis screening program: who does not participate, and what are the consequences? J Am Geriatr Soc 52(7):1130–1137. doi:10.1111/j.1532-5415.2004.52311.x
35. Washington State Department of Health, Center for health statistics. Death data. http://www.doh.wa.gov/ehsphl/CHS/chs-data/death/deatmain.htm. Accessed 15 June 2011
36. Arterburn D, Ichikawa L, Ludman EJ, Operskalski B, Linde JA, Anderson E, Rohde P, Jeffery RW, Simon GE (2008) Validity of clinical body weight measures as substitutes for missing data in a randomized trial. Obes Res Clin Pract 2(4):277–281. doi:10.1016/j.orcp.2008.09.002
37. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25(15):2127–2132. doi:10.1200/JCO.2006.10.3523
38. Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C (2010) Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care 48(6 Suppl):S96–105. doi:10.1097/MLR.0b013e3181d99107
39. Wirtz HS, Boudreau DM, Gralow JR, Barlow WE, Gray S, Bowles EJ, Buist DS (2014) Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors. Breast Cancer Res Treat 143(3):541–550. doi:10.1007/s10549-013-2816-3
40. Bayley KB, Belnap T, Savitz L, Masica AL, Shah N, Fleming NS (2013) Challenges in using electronic health record data for CER: experience of 4 learning organizations and solutions applied. Med Care 51(8 Suppl 3):80–86. doi:10.1097/MLR.0b013e31829b1d48
41. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S (2006) Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119(1):236–238. doi:10.1002/ijc.21812
42. Grundy SM (2007) Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 92(2):399–404. doi:10.1210/jc.2006-0513
43. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D (2012) Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35(11):2402–2411. doi:10.2337/dc12-0336
44. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B (2005) Diabetes mellitus and breast cancer. Lancet Oncol 6(2):103–111. doi:10.1016/S1470-2045(05)01736-5
45. Kiderlen M, de Glas NA, Bastiaannet E, Engels CC, van de Water W, de Craen AJ, Portielje JE, van de Velde CJ, Liefers GJ (2013) Diabetes in relation to breast cancer relapse and all-cause mortality in elderly breast cancer patients: a FOCUS study analysis. Ann Oncol 24(12):3011–3016. doi:10.1093/annonc/mdt367
46. Peeters PJ, Bazelier MT, Vestergaard P, Leufkens HG, Schmidt MK, de Vries F, De Bruin ML (2013) Use of metformin and survival of diabetic women with breast cancer. Curr Drug saf 8(5):357–363
47. Goodwin PJ ClinicalTrials.gov: A phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer NCT01101438. Accessed 18 Feb 2014
48. Li CI, Daling JR, Porter PL, Tang MT, Malone KE (2009) Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol 27(32):5312–5318. doi:10.1200/JCO.2009.23.1597
49. Dignam JJ, Wieand K, Johnson KA, Raich P, Anderson SJ, Somkin C, Wickerham DL (2006) Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res Treat 97(3):245–254. doi:10.1007/s10549-005-9118-3
50. Li CI, Malone KE, Porter PL, Daling JR (2003) Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer 89(3):513–518. doi:10.1038/sj.bjc.6601042
51. Trentham-Dietz A, Newcomb PA, Nichols HB, Hampton JM (2007) Breast cancer risk factors and second primary malignancies among women with breast cancer. Breast Cancer Res Treat 105(2):195–207. doi:10.1007/s10549-006-9446-y
52. Brooks JD, John EM, Mellemkjaer L, Reiner AS, Malone KE, Lynch CF, Figueiredo JC, Haile RW, Shore RE, Group WSC, Bernstein JL, Bernstein L (2012) Body mass index and risk of second primary breast cancer: the WECARE Study. Breast cancer Res Treat 131(2):571–580. doi:10.1007/s10549-011-1743-4
53. Brooks JD, Bernstein L, Teraoka SN, Knight JA, Mellemkjaer L, John EM, Malone KE, Reiner AS, Lynch CF, Concannon P, Haile RW, Bernstein JL, Group WSC (2012) Variation in genes related to obesity, weight, and weight change and risk of contralateral breast cancer in the WECARE Study population. Cancer Epidemiol Biomark Prev 21(12):2261–2267. doi:10.1158/1055-9965.EPI-12-1036
54. Bernstein JL, Thompson WD, Risch N, Holford TR (1992) Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol 136(8):925–936
55. Li CI, Daling JR, Tang MT, Malone KE (2011) Relationship between diabetes and risk of second primary contralateral breast cancer. Breast Cancer Res Treat 125(2):545–551. doi:10.1007/s10549-010-1035-4
56. Gaard M, Tretli S, Urdal P (1994) Risk of breast cancer in relation to blood lipids: a prospective study of 31,209 Norwegian women. Cancer Causes Control 5(6):501–509
57. Manjer J, Kaaks R, Riboli E, Berglund G (2001) Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the Malmo Preventive Project. Eur J Cancer Prev 10(1):33–42
58. Hoyer AP, Engholm G (1992) Serum lipids and breast cancer risk: a cohort study of 5,207 Danish women. Cancer Causes Control 3(5):403–408
59. Agurs-Collins T, Kim KS, Dunston GM, Adams-Campbell LL (1998) Plasma lipid alterations in African–American women with breast cancer. J Cancer Res Clin Oncol 124(3–4):186–190
60. Michalaki V, Koutroulis G, Syrigos K, Piperi C, Kalofoutis A (2005) Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Mol Cell Biochem 268(1–2):19–24
61. Ray G, Husain SA (2001) Role of lipids, lipoproteins and vitamins in women with breast cancer. Clin Biochem 34(1):71–76
62. Bertelsen L, Bernstein L, Olsen JH, Mellemkjaer L, Haile RW, Lynch CF, Malone KE, Anton-Culver H, Christensen J, Langholz B, Thomas DC, Begg CB, Capanu M, Ejlertsen B, Stovall M, Boice JD, Jr., Shore RE, Women’s Environment C, Radiation Epidemiology Study Collaborative G, Bernstein JL (2008) Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women’s Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst 100(1):32–40. doi:10.1093/jnci/djm267
63. Liu CL, Yang TL (2003) Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat 79(1):11–16
64. Hillier TA, Rizzo JH, Pedula KL, Cauley JA, Schwartz AV, Ensrud KE, Browner WS (2005) Increased mortality associated with the metabolic syndrome in older women with diabetes. Diabetes Care 28(9):2258–2260
65. Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287(3):356–359